Innovative Medicines Canada Statement Regarding the Potential Disclosure of Proprietary or Commercially-Sensitive Business Information

Posted on October 26, 2020

Ottawa, October 23, 2020—Innovative Medicines Canada (IMC) issued the following statement in response to the potential disclosure of proprietary or confidential business information regarding the procurement of COVID-19 medicines and vaccines, and other related products:

“Canada’s innovative medicines companies have collaborated in unprecedented ways—with governments, with each other, with patients, and with researchers—throughout the pandemic to find medicines to treat those infected with the virus and vaccines to prevent its spread.

“As part of the fight against COVID-19, several IMC member companies have entered into confidential agreements with the government to provide potential vaccines.

“These companies entered into those agreements on the assumption that commercially-sensitive and proprietary information would remain confidential. The public disclosure of such information could have a negative impact on the very companies that are working to help protect Canadians from the virus.

“We urge all involved to ensure that commercially-sensitive and proprietary information is protected from disclosure at this critical time.”

About Innovative Medicines Canada

Innovative Medicines Canada is the national voice of Canada’s innovative pharmaceutical industry. We advocate for policies that enable the discovery, development and commercialization of innovative medicines and vaccines that improve the lives of all Canadians. We support our members’ commitment to being valued partners in the Canadian healthcare system.

– 30 –

For further information:

Samantha Thompson
Media Relations
Telephone: 613-790-4555
E-mail: sthompson@imc-mnc.ca

Leave a Reply

Your email address will not be published. Required fields are marked *